Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Dar Global

    MCap

    USD1,486m

    Last close

    USD8.25

    ▲ −0.25 (−2.94%)

    Theon International

    MCap

    EUR875m

    Last close

    EUR12.36

    ▲ −0.14 (−1.12%)

    Metals One

    MCap

    GBP2m

    Last close

    GBP0.00

    ▲ −0.06 (−12.24%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – RhoVac

Executive interview – RhoVac

Chosa — 1 video in collection

More on this equity

RhoVac is developing RV001, a cancer immunotherapy designed to prevent or limit metastasis by activating T-cells against cells with metastatic potential. The therapy contains fragments of the protein RhoC, which is overexpressed in cells with metastatic potential across a range of cancers. The ongoing Phase IIb study in prostate cancer is fully funded and results are expected around mid-2021. RhoVac’s strategic aim is to secure a partner for the late-stage development of RV001. In this video, Anders Månsson, RhoVac’s chief executive officer, introduces the company and its lead asset, RV001 and provides an overview of R&D progress and expected newsflow.

< Previous
Next >

You may also be interested in these:

Healthcare

Mendus – executive interview

Healthcare

Oryzon Genomics – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free